To align the incentives of all stakeholders involved in the patients’ healthcare journey related to sustainable strategies to improve medication adherence and persistence in patients with Type 2 diabetes.
Established under a Research Collaboration Agreement with the U.S. Food and Drug Administration (FDA), the P-MAPP links comprehensive longitudinal patient-centric data, acquired in the "voice of the patient" via customized surveys, with information contained in patient health records, pharmacy fill/refill information and medical claims to create a de-identified, aggregated database of real world medication adherence/persistence and clinical outcomes.
The P-MAPP is unique in its randomized design, implementation in multiple pharmacy settings and use of predictive analytics to define drivers of non-adherence behaviours.
P-MAPP’s distinctive platform combines digital technologies, predictive analytics, and provider engagement to create personalized intervention strategies to address, monitor, and modify patients’ behaviors related to medication non-adherence.
The P-MAPP includes many "FIRSTS":
“The patient is the most underused resource in healthcare.”